Prediction-market platform Kalshi is moving into one of the highest-stakes corners of medicine: the success or failure of new drugs.
According to Bloomberg's Madison Muller, Kalshi is now offering wagers on the outcomes of late-stage clinical drug trials and on regulatory decisions. The company is launching the effort as a pilot built around 13 new biotech contracts.
Kalshi operates markets where people can bet real money on whether a specific event will happen. Applied to biotech, that means users can effectively place a wager on questions such as whether a company's late-stage trial will hit its goals, or whether regulators will approve a given treatment. Bloomberg reported the news under the headline "Kalshi to Offer Betting on Drug Trial Results."
Late-stage trials are the final, most expensive proving grounds a drug must clear before it can reach patients, and their results routinely swing the fortunes of the companies behind them. Regulatory rulings carry similar weight. Those outcomes have long been the subject of intense speculation among investors and analysts, but Kalshi's move turns that speculation into a directly tradable contract open to a broader set of participants.
Beyond the individual contracts, the launch is a signal of how far prediction markets are pushing into specialized, information-heavy fields. Platforms like Kalshi have drawn attention for markets on elections, economic data and cultural events; extending into biotech applies the same mechanism to scientific and medical events whose results can be difficult even for experts to forecast.
The details available so far are limited to what Bloomberg reported: the focus on late-stage trials and regulatory decisions, and the 13-contract pilot. The reporting does not specify which drugs or companies are covered, or the size limits on wagers.
Why it matters: If betting markets can price the odds of a drug succeeding, they could become a new public gauge of medical risk — while also raising fresh questions about wagering on outcomes that determine which treatments reach patients.